About: Enzyme immunoassay for SARS-CoV-2 antibodies in dried blood spot samples: A minimally-invasive approach to facilitate community- and population-based screening

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Enzyme immunoassay for SARS-CoV-2 antibodies in dried blood spot samples: A minimally-invasive approach to facilitate community- and population-based screening Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Enzyme immunoassay for SARS-CoV-2 antibodies in dried blood spot samples: A minimally-invasive approach to facilitate community- and population-based screening
Creator	Miller, Aaron Bogdanovic, Elena D'aquila, Richard Demonbreun, Alexis Mcdade, Thomas Mcnally, Elizabeth Mustanski, Brian Reiser, Nina Vaught, Lauren Zelikovich, Aaron
Source	MedRxiv
abstract	Background Serological testing for SARS-CoV-2 IgG antibodies is needed to document the community prevalence and distribution of the virus, particularly since many individuals have mild symptoms and cannot access molecular diagnostic testing of naso-pharyngeal swabs. However, the requirement for serum/plasma limits serological testing to clinical settings where it is feasible to collect and process venous blood. To address this problem we developed a serological test for SARS-CoV-2 IgG antibodies that requires only a single drop of capillary whole blood, collected from a simple finger prick and dried on filter paper (dried blood spot, DBS). Methods Enzyme linked immunosorbent assay (ELISA) was optimized to detect SARS-CoV-2 IgG antibodies against the receptor-binding domain (RBD) of the spike protein. DBS samples were eluted overnight and transferred to a 96-well plate coated with antigen, and anti-human IgG-HRP was used to generate signal in proportion to bound antibody. DBS samples spiked with anti-SARS IgG antibody, and samples from known positive and negative cases, were compared to evaluate assay performance. Results Analysis of samples with known concentrations of anti-SARS IgG produced the expected pattern of dose-response. Optical density (OD) values were significantly elevated for known positive cases in comparison with samples from unexposed individuals. Discussion DBS ELISA provides a minimally-invasive alternative to venous blood collection that combines the convenience of sample collection in the home or non-clinical setting with the accuracy of ELISA in the lab. Serological testing for SARS-CoV-2 IgG antibodies in DBS samples should facilitate research across a wide range of community- and population-based settings on seroprevalence, predictors and duration of antibody responses, as well as correlates of protection from reinfection, each of which is critically important for pandemic control.
has issue date	2020-05-04(xsd:dateTime)
bibo:doi	10.1101/2020.04.28.20081844
has license	medrxiv
sha1sum (hex)	c54cd8c5ebf9df6d8a5c91318b7a47cbe48d3b20
schema:url	https://doi.org/10.1101/2020.04.28.20081844
resource representing a document's title	Enzyme immunoassay for SARS-CoV-2 antibodies in dried blood spot samples: A minimally-invasive approach to facilitate community- and population-based screening
resource representing a document's body	covid:c54cd8c5ebf9df6d8a5c91318b7a47cbe48d3b20#body_text
is schema:about of	named entity 'individuals' named entity 'finger prick' named entity 'minimally-invasive' named entity 'blood' named entity 'DOCUMENT ' named entity 'SEROLOGICAL TEST' named entity 'LIMITS' named entity 'CLINICAL SETTINGS' named entity 'SWABS' covid:arg/c54cd8c5ebf9df6d8a5c91318b7a47cbe48d3b20 named entity 'blood' named entity 'SARS-CoV-2' named entity 'molecular diagnostic' named entity 'capillary' named entity 'virus' named entity 'IgG antibodies' named entity 'pharyngeal' named entity 'virus' named entity 'SARS-CoV-2' named entity 'non-clinical' named entity 'US Postal Service' named entity 'lateral flow immunoassay' named entity 'IgG antibodies' named entity 'virus' named entity 'global pandemic' named entity 'DBS' named entity 'COVID' named entity 'preprint' named entity 'Serological testing' named entity 'finger stick' named entity 'Princeton, New Jersey' named entity 'adversely affect' named entity 'milk' named entity 'false negative results' named entity 'infection' named entity 'infection' named entity 'health research' named entity 'infection' named entity 'DBS' named entity 'PBS' named entity 'PCR' named entity 'infection' named entity 'medRxiv' named entity 'PBS' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'RBD' named entity 'SARS-CoV' named entity 'PBS' named entity 'chromatography' named entity 'RBD' named entity 'DBS' named entity 'Assay' named entity 'preprint' named entity 'dose-response' named entity 'viral RNA' named entity 'community spread' named entity 'DBS' named entity 'vaccine' named entity 'IgG' named entity 'cold chain' named entity 'color forms' named entity 'hemolysis' named entity 'IgG antibodies' named entity 'DBS' named entity 'antibody complexes' named entity 'DBS' named entity 'gene' named entity 'DBS' named entity 'glycoprotein' named entity 'antibody' named entity 'coronavirus disease 2019' named entity 'Assay' named entity 'SARS-CoV-2' named entity 'RBD' named entity 'host cells'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software